Navigation Links
Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
Date:10/31/2007

PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.

-- Novo Nordisk increased sales by 14% in local currencies and by 9% in

Danish kroner due to a significant negative currency development.

-- Sales of modern insulins increased by 37% (31% in Danish kroner).

-- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner).

-- Sales of Norditropin(R) increased by 12% (7% in Danish kroner).

-- Sales in North America increased by 25% (15% in Danish kroner).

-- Gross margin increased to 76.7% in the first nine months of 2007 up

from 75.2% in the same period last year, primarily reflecting continued

productivity improvements.

-- Operating profit increased by 11% to USD 1,410 million. Adjusted for

the impact from currencies, underlying operating profit increased by

more than 20%.

-- Net profit increased by 60% to USD 1,361 million, primarily reflecting

the divestment of Dako's business activities in the second quarter of

2007. Earnings per share (diluted) increased by 62% to USD 4.26.

-- The expectation for full-year sales growth is still 11-14% measured in

local currencies and now 6-9% as reported due to the depreciation of

key invoicing currencies. Full-year operating profit growth remains

unchanged around 20% measured in local currencies and is now expected

to be close to 10% as reported.

-- In October, Novo Nordisk received marketing authorization for

Levemir(R) in Japan for both type 1 and type 2 diabetes including

combination treatment with oral antidiabetics.

Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern insulins continues to show strong sales growth in all key markets. Within the next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which will further support growth in the coming years."

* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.54317.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. cMaster RTplusPCR System for increased sensitivity and product length in RT-PCR
2. Increased Sensitivity in Microarray Analysis
3. Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell
4. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
5. VC funding increased in third quarter with shining life sciences
6. Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter
7. Alfalight Gets $3.8M From DARPA - Funding has increased to $8.5 Million
8. Brinkmann/Eppendorf SOP Standard Operating Procedure for Pipettes
9. Sonic Foundry posts explosive growth, though still operating at a loss
10. Fiserv reports $113.5 million in Q1 profit
11. Re-engineering our economy to be sustainable and profitable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):